Transplantation for AML in Children

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Carpenter, Paul A ^a   Meshinchi, Soheil ^a   Davies, Stella M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AZACITIDINE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHILDHOOD LEUKEMIA; CLINICAL DECISION MAKING; DONOR LYMPHOCYTE INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC RISK; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOSPITALIZED CHILD; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; ORGAN DONOR; OVERALL SURVIVAL; RADIATION DOSE FRACTIONATION; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DONOR SELECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855379199     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.035     Document Type: Article

References (57)

1. Sanders J.E., Thomas E.D., Buckner C.D., et al. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. Blood 1985, 66:460-462.
2. Ravindranath Y., Chang M., Steuber C.P., et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005, 19:2101-2116.
3. Gibson B.E., Wheatley K., Hann I.M., et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005, 19:2130-2138.
4. Boo M., Ballen K., Maiers M. Cord blood unit access and selection: 2010 and beyond: best practices and emerging trends in cord blood unit selection. Biol Blood Marrow Transplant 2011, 17:S46-S51.
5. Confer D., Robinett P. The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42(Suppl 1):S3-S5.
6. Woods W.G., Kobrinsky N., Buckley J., et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children's Cancer Group pilot study. J Clin Oncol 1993, 11:1448-1457.
7. Woods W.G., Neudorf S., Gold S., et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97:56-62.
8. Ho P.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009, 113:6558-6566.
9. Brown P., McIntyre E., Rau R., et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007, 110:979-985.
10. Meshinchi S., Alonzo T.A., Stirewalt D.L., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108:3654-3661.
11. Alonzo T.A., Ho P.A., Gerbing R.B., et al. Conventional cytogenetics, molecular profiling, and flow cytometric response data allow the creation of a 2-tiered risk-group system for risk-based therapy allocation in childhood AML-a report from the Children's Oncology Group. ASH Annu Meet Abstr 2010, 116:761.
12. Bunin N.J., Davies S.M., Aplenc R., et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. JClin Oncol 2008, 26:4326-4332.
13. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008, 20:581-587.
14. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12:828-836.
15. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
16. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
17. Lowe E.J., Turner V., Handgretinger R., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326.
18. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100:3825-3827.
19. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
20. Bari R., Leung M., Turner V.E., et al. Molecular determinant-based typing of KIR alleles and KIR ligands. Clin Immunol 2011, 138:274-281.
21. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
22. Leung W., Iyengar R., Triplett B., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174:6540-6545.
23. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
24. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001, 98:3569-3574.
25. Ringden O., Labopin M., Tura S., et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996, 93:637-645.
26. Helenglass G., Powles R.L., McElwain T.J., et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988, 3:21-29.
27. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of 2 irradiation regimens. Blood 1990, 76:1867-1871.
28. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
29. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
30. Horan J.T., Logan B.R., Agovi-Johnson M.A., et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. J Clin Oncol 2011, 29:805-813.
31. MacMillan M.L., Davies S.M., Nelson G.O., et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:16-22.
32. Horan J.T., Alonzo T.A., Lyman G.H., et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol 2008, 26:5797-5801.
33. Wiedemann B., Klyuchnikov E., Kroger N., et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol 2010, 38:1261-1271.
34. Bader P., Klingebiel T., Schaudt A., et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999, 13:2079-2086.
35. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29:1190-1197.
36. Rosenberg A.R., Leisenring W., Sanders J.E., et al. Sub-morphologic evidence of disease prior to stem cell transplantation correlates with inferior post transplant outcome in childhood acute myeloid leukemia. ASH Annu Meet Abstr 2009, 114:328.
37. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010, 28:3730-3738.
38. Pagel J.M., Gooley T.A., Rajendran J., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia orhigh-risk myelodysplastic syndrome. Blood 2009, 114:5444-5453.
39. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and earlyclinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
40. Magenau J., Tobai H., Pawarode A., et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant anti-tumor activity in non-remission hematologic malignancies. Blood 2011, 118:4258-4264.
41. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
42. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
43. Karon M., Sieger L., Leimbrock S., et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973, 42:359-365.
44. Metzelder S., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
45. Elmaagacli A.H., Beelen D.W., Trenn G., et al. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:771-777.
46. Mielcarek M., Storer B.E., Flowers M.E., et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1160-1168.
47. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
48. Huang X.J., Wang Y., Liu D.H., et al. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009, 44:309-316.
49. Klingbiel T., Bader P. Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant 2008, 41:S23-S26.
50. Solh M., Defor T.E., Weisdorf D.J., et al. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transplant 2011, [Epub ahead of print].
51. Mayadev J.S., Douglas J.G., Storer B.E., et al. Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. Int J Radiat Oncol Biol Phys 2011, 80:193-198.
52. Bosi A., Laszlo D., Labopin M., et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001, 19:3675-3684.
53. Eapen M., Giralt S.A., Horowitz M.M., et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.
54. Meshinchi S., Leisenring W.M., Carpenter P.A., et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003, 9:706-713.
55. Radich J.P., Gooley T., Sanders J.E., et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000, 6:272-279.
56. Bleakley M., Otterud B.E., Richardt J.L., et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by invitro stimulation of naive CD8+ Tcells. Blood 2010, 115:4923-4933.
57. Warren E.H., Fujii N., Akatsuka Y., et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115:3869-3878.